EBIT at other companies
Other financials
Where this comes from
Calculated from Esperion Therapeutics’s reported figures.
Plus components not separately reported this period.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's EBIT?
- Esperion Therapeutics (ESPR) reported EBIT of -$6.58M in Q1 2026.
- How has Esperion Therapeutics's EBIT changed year-over-year?
- Esperion Therapeutics's EBIT increased by 70.2% year-over-year, from -$22.1M to -$6.58M.
- What is the long-term trend for Esperion Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Esperion Therapeutics's EBIT has grown at a -28.2% compound annual growth rate (CAGR), from -$226.73M to $60.27M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.